Coya posts wider losses, $29.8M runway; DRL partnership and Aug 29 IND decision key

Coya Therapeutics, Inc. (NASDAQ: COYA) - quick read on the company's Q2 2025 situation and income-statement health.

At a glance

* Cash (6/30/2025): $29,757,328
* Total assets (6/30/2025): $33,452,555
* Total liabilities (6/30/2025): $5,142,262
* Stockholders' equity (6/30/2025): $28,310,293
* Accumulated deficit (6/30/2025): $(54,138,904)
* Shares outstanding (8/8/2025): 16,725,081
* Weighted-average shares (6/30/2025): 16,724,998

Quarter / Six‑month financials

* Collaboration revenue - Q2 2025: $163,616 (Q2 2024: $3,425,271)
* Collaboration revenue - YTD 6/30/2025: $421,500 (YTD 2024: $3,552,109)
* R&D expense - Q2 2025: $3,663,103 (Q2 2024: $4,566,152)
* G&A expense - Q2 2025: $2,908,191 (Q2 2024: $2,088,404)
* Total operating expenses - Q2 2025: $6,578,134
* Net loss - Q2 2025: $(6,094,977) (Q2 2024: $(2,891,680)) - Net loss per share Q2: $(0.36)
* Net loss - YTD 6/30/2025: $(13,401,734) (YTD 2024: $(7,943,593)) - YTD loss per share: $(0.80)

Cash flow / runway

* Cash used in operating activities - YTD: $(8,601,571)
* Net change in cash - YTD: $(8,582,434) (beginning cash $38,339,762 → $29,757,328)
* Company assessment: cash expected to fund operations for at least one year after the financial statements were issued, but additional financing required thereafter.

Capital structure / dilution pressure

* Stock options outstanding (6/30/2025): 2,963,795
* Common stock warrants outstanding (6/30/2025): 815,677
* Potential common share equivalents excluded from diluted EPS (6/30/2025): 3,779,472
* Unrecognized stock‑based comp: $7.1 million to be expensed over ~1.9 years.

What's happening inside the company

* Science & IP: Coya is advancing its Treg-enhancing platform (COYA 301/302/303). Published preclinical results for COYA 303 (April 21, 2025) showing a 42% increase in Treg suppressive function vs. single agents; a U.S. patent for an IL‑2 formulation was issued June 2, 2025. These are real R&D progress points that de‑risk some technical elements.

* Partnership: The DRL (Dr. Reddy's) collaboration remains central. The company recognized license revenue earlier (2024) and is now recognizing R&D services revenue as work progresses; deferred collaboration revenue was $1,372,233 at 6/30/2025 (beginning balance $1,793,733).

* Development timing: IND for COYA 302 was re‑submitted; FDA delayed initial review due to workload and expects a decision no later than August 29, 2025. That timing is a critical near-term catalyst (or gating item).

Income statement - positives

* Cash balance provides a runway: $29.8M is meaningful for a small clinical-stage biotech and management states it funds operations for at least ~1 year.
* R&D discipline: R&D spend dipped Q/Q in the quarter (preclinical ramp timing), showing some control over program pacing.
* Partner support and milestone structure: DRL collaboration has delivered meaningful upfront payments historically ($7.5M upfront; $3.9M First Amendment payment) and provides milestone/royalty upside that could be non‑dilutive if achieved.

Income statement - negatives

* Losses are widening: Net loss doubled YTD vs prior year ($13.4M vs $7.9M) and Q2 loss more than doubled versus prior year quarter - cash burn is accelerating.
* Revenue base is thin and lumpy: Collaboration revenue collapsed versus prior year quarter due to prior period license recognition; predictable product revenue is years away.
* Rising G&A and stock compensation: G&A rose (professional services, investor relations) and stock‑based comp is large ($2.1M YTD), adding to non‑cash expense and potential future dilution.
* Going concern / funding risk: Company acknowledges need for substantial additional funding beyond the stated ~1‑year runway - failure to raise funds would force cutbacks or dilution.

Key catalysts & risks - short

* Upcoming IND decision (COYA 302): FDA review delayed; decision expected by no later than August 29, 2025 - approval to proceed would enable the planned Phase 2 ALS study and be a major operational inflection.
* Funding need: Management expects to require additional capital after the ~1‑year runway; financing terms and timing are major near‑term risks (dilution or strategic partnerships likely).
* Milestones from DRL: future milestone payments and royalties could materially improve the cash profile if achieved - but they are contingent and long‑dated.
* Clinical & execution risk: scientific promise (publications, patent) contrasts with typical clinical risk for novel biologics; program success is not guaranteed.

Bottom line

Coya (NASDAQ: COYA) is a clinical‑stage biotech with promising science, partnership upside via Dr. Reddy's, and newly issued IP - but it is burning cash faster, reporting larger losses year‑over‑year, and will need new financing within roughly a year. The next big read for investors is the FDA IND decision (expected by Aug 29, 2025); financing strategy and milestone realization will determine whether the company can bridge to clinical value‑creation without significant dilution.